Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9
First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9
Locations
1
Syria
Tishreen University
Latakia, Syria
Start Date
January 4, 2021
Primary Completion Date
June 21, 2022
Completion Date
July 1, 2022
Last Updated
March 3, 2022
NCT05529069
NCT06189391
NCT05006716
NCT06026319
NCT05442515
NCT06745076
Lead Sponsor
Tishreen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions